BUZZ-AnaptysBio slumps after abandoning eczema drug development
** Shares of AnaptysBio ANAB.O fall as much as 38.5% to an over one-year low of $14.20
** Stock set for worst day since Nov 2019, if losses hold
** Co says it will discontinue development of its eczema drug ANB032 after it failed to meet the goals of a mid-stage trial
** Drug did not meet the main goal of a proportion of patients achieving an at least 75% improvement of symptoms on an eczema severity index
** ANAB will focus on the rest of its autoimmune portfolio, which includes drugs for rheumatoid arthritis and a type of inflammatory bowel disease - CEO
** Up to last close, stock down 30.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available